---
document_datetime: 2025-01-06 14:31:44
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/deferasirox-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: deferasirox-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 2.5317373
conversion_datetime: 2025-12-30 00:13:29.241009
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Deferasirox Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                          |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0011               | Renewal of the marketing authorisation. | 19/09/2024                          | 28/11/2024                                  | SmPC, Annex II and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Deferasirox Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0012           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                 | 18/06/2024   | 06/09/2024   | SmPC, Annex II, Labelling and PL   |                                   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| IA/0010           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                 | 03/04/2024   | n/a          |                                    |                                   |
| IB/0009/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/09/2023   | 06/09/2024   | SmPC                               |                                   |
| PSUSA/939/2 02210 | Periodic Safety Update EU Single assessment - deferasirox                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/06/2023   | n/a          |                                    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0008   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                     | 31/05/2023   | n/a        |                        |                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------|
| IB/0005/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing including the RMP - Other variation | 15/03/2023   | 04/04/2023 | SmPC, Annex II and PL  | authorisation, |
| IAIN/0007 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                         | 25/01/2023   | n/a        |                        |                |
| IB/0003   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                  | 04/02/2022   | n/a        |                        |                |
| IB/0004   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                            | 21/12/2021   | 24/06/2022 | SmPC, Labelling and PL |                |

<div style=\"page-break-after: always\"></div>

| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 31/08/2021   | 24/06/2022   | PL   |                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|----------------------------------------------------------------------------------------------------|
| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                      | 18/06/2021   | 24/06/2022   | SmPC | To extend the shelf-life of the finished product as packaged for sale from 24 months to 36 months. |